Monitoring Chemotherapeutic Response by Hyperpolarized 13C-Fumarate MRS and Diffusion MRI
- 1 February 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (3), 686-694
- https://doi.org/10.1158/0008-5472.can-13-1914
Abstract
Targeted chemotherapeutic agents often do not result in tumor shrinkage, so new biomarkers that correlate with clinical efficacy are needed. In this study, we investigated noninvasive imaging protocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal cell and hepatocellular carcinoma. Healthy cells are impermeable to fumarate, so conversion of this metabolite to malate as detected by 13C-magnetic resonance spectroscopy (MRS) has been suggested as one marker for cell death and treatment response in tumors. Diffusion MRI also has been suggested as a measure of therapy-induced cytotoxic edema because viable cells act as a diffusion barrier in tissue. For these reasons, we assessed sorafenib responses using hyperpolarized 13C-fumarate, diffusion-weighted MRI (DW-MRI) in a xenograft model of human breast cancer in which daily administration of sorafenib was sufficient to stabilize tumor growth. We detected signals from fumarate and malate following intravenous administration of hyperpolarized fumarate with a progressive increase in the malate-to-fumarate (MA/FA) ratio at days 2 to 5 after sorafenib infusion. The apparent diffusion coefficient (ADC) measured by DW-MRI increased in the treated group consistent with cytotoxic edema. However, the MA/FA ratio was a more sensitive marker of therapeutic response than ADC, with 2.8-fold versus 1.3-fold changes, respectively, by day 5 of drug treatment. Histologic analyses confirmed cell death in the sorafenib-treated cohort. Notably, 13C-pyruvate-to-lactate conversion was not affected by sorafenib in the breast cancer model examined. Our results illustrate how combining hyperpolarized substrates with DW-MRI can allow noninvasive monitoring of targeted therapeutic responses at relatively early times after drug administration. Cancer Res; 74(3); 686–94. ©2013 AACR.Keywords
This publication has 51 references indexed in Scilit:
- Phase I trial of sorafenib in patients with recurrent or progressive malignant gliomaNeuro-Oncology, 2011
- Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasCancer, 2011
- Hyperpolarized [1-13C]-Ascorbic and Dehydroascorbic Acid: Vitamin C as a Probe for Imaging Redox Status in VivoJournal of the American Chemical Society, 2011
- Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopyMagnetic Resonance in Medicine, 2011
- Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1‐13C]pyruvate and 13C magnetic resonance spectroscopic imagingMagnetic Resonance in Medicine, 2010
- Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarateBritish Journal of Cancer, 2010
- Production of hyperpolarized [1,4- 13 C 2 ]malate from [1,4- 13 C 2 ]fumarate is a marker of cell necrosis and treatment response in tumorsProceedings of the National Academy of Sciences of the United States of America, 2009
- Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopyBritish Journal of Cancer, 2009
- Kinetics of hyperpolarized 13 C 1 -pyruvate transport and metabolism in living human breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- DNP-Hyperpolarized 13C Magnetic Resonance Metabolic Imaging for Cancer ApplicationsApplied Magnetic Resonance, 2008